Andrea Necchi: Phase I (TEM-GU) study is recruiting patients with metastatic clear cell renal carcinoma
Oct 31, 2024, 12:50

Andrea Necchi: Phase I (TEM-GU) study is recruiting patients with metastatic clear cell renal carcinoma

Andrea Necchi, Associate Editor at Journal of Clinical Oncology, posted the following on X:

“Happy to share this innovative phase I (TEM-GU) study is now active and recruiting patients with metastatic clear cell RCC who have a disease progressing after at least 2 lines of treatment including IO and a VEGF-TKI.

Temferon is a gene therapy with hematopoietic stem cells designed to reprogram the tumor microenvironment by delivering immunomodulatory molecules directly to tumors.”